Intramolecular signaling in immunoglobulins - New evidence emerging from the use of supramolecular protein ligands

Journal of Physiology and Pharmacology

Volumn 55, Issue 3, 2004, Pages 487-501

  Piekarska, Barbara ^a   Konieczny, L ^a   Rybarska, J ^a   Stopa, B ^a   Spolnik P ^b   Roterman, I ^a   Krol M ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b NONE

Author keywords

Antibody; Congo red; Immune complexes; Intramolecular signaling

Indexed keywords

ANTIGEN; AZO DYE; CONGO RED; IMMOBILIZED ANTIGEN; IMMUNOGLOBULIN; LIGAND; PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; CONFORMATIONAL TRANSITION; INTRAMOLECULAR SIGNALING; LIGAND BINDING; MOLECULAR INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SUPRAMOLECULAR CHEMISTRY;

ANTIGEN-ANTIBODY COMPLEX; BINDING SITES; COLORING AGENTS; CONGO RED; IMMUNOGLOBULINS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 4844226601     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Feinstein A, Rowe AJ. Molecular mechanism of formation of an antigen - antibody complex. Nature 1965; 205: 147-149.
2. Edelman GM. The covalent structure of human γG-immunoglobulin. XI. Functional implications. Biochemistry 1970; 9: 3197-3205.
3. Calvanico NJ, Tomasi TB Jr. Effector sites on antibodies. In: Atassi MZ, editor, Immunochemistry of proteins, vol 3. New York and London: Plenum Press, 1979. p.1-85.
4. Weininger RB, Richards FF. Combining regions of antibodies. In: Atassi MZ, editor. Immunochemistry of proteins, vol 3. New York and London: Plenum Press, 1979. p. 123-166.
5. 13C nuclear magnetic resonance spectroscopy. J Mol Biol 1994; 236: 300-309.
6. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol 1998; 161: 4083-4090.
7. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol Today 1995; 16: 85-90.
8. Harris LJ, Larson SB, McPherson A. Comparison of intact antibody structures and the implications for effector function. Adv Immunol 1999; 72: 191-208.
9. 1. J Immunol 1997; 158: 733-740.
10. Kilár F, Simon I, Lakatos S, Vonderviszt F, Medgyesi GA, Závodszky P. Conformation of human IgG subclasses in solution - Small-angle X-ray scattering and hydrodynamic studies. Eur J Biochem 1985; 147: 17-25.
11. Burton DR. Structure and function of antibodies. In: Calabi F, Neuberger MS, editors. Molecular genetics of immunoglobulin. Amsterdam: Elsevier, 1987. p. 1-50.
12. Burton DR. The conformation of antibodies. In: Metzger H, editor. Fc receptors and the action of antibodies. Washington D.C: Am Soc Microbiol 1990. p.31-56.
13. Schumaker VN, Calcott MA, Spiegelberg HL, Müller-Eberhard HJ. Ultracentrifuge studies of the binding of IgG of different subclasses to the C1q subunit of the first component of complement. Biochemistry 1976; 15: 5175-5181.
14. Cathou RE. Solution conformation and segmental flexibility of immunoglobulins. In: Litman GW, Good RA, editors. Immunoglobulins. New York and London: Plenum Medical Book Company. Comprehensive Immunology, vol. 5. 1978. p.37-83.
15. Kratz HJ, Borsos T, Isliker H. Mouse monoclonal antibodies at the red cell surface - II. Effect of hapten density on complement fixation and activation. Mol Immunol 1985; 22: 229-235.
16. Kehoe JM. The structural basis for the biological properties of immunoglobulins. In: Litman GW, Good RA, editors. Immunoglobulins. vol. 5. New York London: Plenum Medical Book Company. 1978. p. 173-196.
17. Metzger H. General aspects of antibody structure and function, In: Fc receptors and the action of antibodies. Metzger H. editor. Washington D. C.: Am Soc Microbiol 1990. p.7-11.
18. Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163: 59-76.
19. Schumaker VN, Hanson DC, Kilchherr E, Phillips ML, Poon PH. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol 1986; 23: 557-565.
20. Constantine KL, Friedrichs MS, Metzler WJ, Wittekind M, Hensley P, Mueller L. Solution structure of an isolated antibody VL domain. J Mol Biol 1994; 236: 310-327.
21. Colman PM, Laver WG, Varghese JN, Baker AT, Tulloch PA, Air GM, et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 1987; 326: 358-363.
22. Bhat TN, Bentley GA, Fischmann TO, Boulot G, Poljak RJ. Small rearrangements in structures of Fv and Fab fragments of antibody D1,3 on antigen binding. Nature 1990; 347: 483-485.
23. Schulze-Gahmen U, Rini JM, Wilson IA. Detailed analysis of the free and bound conformations of an antibody. X-ray structures of Fab 17/9 and three different Fab-peptide complexes. J Mol Biol 1993; 234: 1098-1118.
24. Tulip WR, Varghese JN, Webster RG, Laver WG, Colman PM. Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface. J Mol Biol 1992; 227: 149-159.
25. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J Mol Biol 1992; 227: 122-148.
26. Guddat LW, Shan L, Anchin JM, Linthicum DS, Edmundson AB. Local and transmitted conformational changes on complexation of an anti-sweetener Fab. J Mol Biol 1994; 236: 247-274.
27. Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 1994; 4: 857-867.
28. Pilz I, Kratky O, Licht A, Sela M. Shape and volume of fragments Fab′ and (Fab′)2 of antipoly(D-alanyl) antibodies in the presence and absence of tetra-D-alanine as determined by small-angle x-ray scattering. Biochemistry 1975; 14: 1326-1333.
29. Loseva OI, Abramov VM, Zav'yalov VP, Troitsky GV, Olsovska Z, Franek F. Conformational changes induced by hapten in pig antibodies to the dinitrophenyl group. Analysis by temperature-perturbation and solvent-perturbation spectroscopy. Eur J Biochem 1982; 121: 631-635.
30. Jaton JC, Huser H, Braun DG, Givol D, Pecht I, Schlessinger J. Conformational changes induced in a homogeneous anti-type III pneumococcal antibody by oligosaccharides of increasing size. Biochemistry 1975; 14: 5312-5315.
31. Schneider WP, Wensel TG, Stryer L, Oi VT. Genetically engineered immunoglobulins reveal structural features controlling segmental flexibility. Proc Natl Acad Sci USA 1988; 85: 2509-2513.
32. H2 influence the relative abilities of IgG2 and IgG3 to activate complement. Mol Immunol 1997; 34: 1019-1029.
33. Tan LK, Shopes RJ, Oi VT, Morrison SL. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci USA 1990; 87: 162-166.
34. H2 domain. J Exp Med 1991; 173: 1025-1028.
35. Sandlie I, Michaelsen TE. Engineering monoclonal antibodies to determine the structural requirements for complement activation and complement mediated lysis. Mol Immunol 1991; 28: 1361-1368.
36. Tao M-H, Smith RIF, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993; 178: 661-667.
37. Mizutani R, Igarashi T, Tanaka T, Shimada I, Arata Y. Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen. J Immunol 1993; 150: 131-138.
38. H2 domains contributes to their differential ability to bind and activate complement. J Biol Chem 1994; 269: 3469-3474.
39. Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. Proc Natl Acad Sci USA 1994; 91: 9243-9247.
40. Brekke OH, Michaelsen TE, Sandin R, Sandlie I. Activation of complement by an IgG molecule without a genetic hinge. Nature 1993; 363: 628-630.
41. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol Today 1995; 16: 85-90.
42. Rybarska J, Konieczny L, Bobrzecka K, Laidler P. The hemolytic activity of (Fab-Fc) recombinant immunoglobulins with specificity for the sheep red blood cells. Immunol Lett 1982; 4: 279-284.
43. Uracz W, Bobrzecka K, Konieczny L, Rybarska J, Zembala M. The use of Fab-Fc recombinant antibodies for studying the mechanism of triggering the effector activities of immunoglobulins. Immunol Lett 1984; 7: 215-220.
44. Klein M, Haeffner-Cavaillon N, Isenman DE, Rival C, Navia MA, Davies DR, et al. Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. Proc Natl Acad Sci USA 1981; 78: 524-528.
45. Ullman EF, Milburn G, Jelesko J, Radika K, Pirio M, Kempe T, et al. Anti-immune complex antibodies enhance affinity and specificity of primary antibodies. Proc Natl Acad Sci USA 1993; 90: 1184-1189.
46. Voss EW Jr, Moore JK, Weidner-McGufficke KM, Denzin LK, Bedzyk WD, Voss VH. Autologous anti-metatype immune response in rabbits. Mol Immunol 1992; 29: 241-249.
47. Pajdak W, Radwan J, Guzik TJ. Cleavage of prothrombin bound in immune complexes results in high thrombin enzymatic activity. J Physiol Pharmacol 2004; 55, 477-484.
48. Rybarska J, Konieczny L, Roterman I, Piekarska B. The effect of azo dyes on the formation of immune complexes. Arch Immunol Ther Exp (Warsz) 1991; 39: 317-327.
49. Stopa B, Górny M, Konieczny L, Piekarska B, Rybarska J, Skowronek M, et al. Supramolecular ligands: Monomer structure and protein ligation capability Biochimie 1998; 80: 963-968.
50. Kaszuba J, Konieczny L, Piekarska B, Roterman I, Rybarska J. Bis-azo dyes interference with effector activation of antibodies. J Physiol Pharmacol 1993; 44: 233-242.
51. Glenner GG, Eanes ED, Page DL. The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation. J Histochem Cytochem 1972; 20: 821-826.
52. Skowronek M, Stopa B, Konieczny L, Rybarska J, Piekarska B, Szneler E, et al. Self-assembly of Congo red - A theoretical and experimental approach to identify its supramolecular organization in water and salt solution. Biopolymers 1998; 46: 267-281.
53. Stopa B, Piekarska B, Konieczny L, Rybarska J, Spólnik P, Zemanek G, et al. The structure and protein binding of amyloid-specific dye reagents. Acta Biochim Pol 2003; 50: 1213-1227.
54. Piekarska B, Rybarska J, Stopa B, Zemanek G, Król M, Roterman I, et al. Supramolecularity creates nonstandard protein ligands. Acta Biochim Pol 1999; 46: 841-851.
55. Rybarska J, Piekarska B, Stopa B, Zemanek G, Konieczny L, Nowak M, et al. Evidence that supramolecular Congo red is the sole ligation form of this dye for L chain λ derived amyloid proteins. Folia Histochem. Cytobiol 2001; 39: 307-314.
56. Iconomidou VA, Chryssikos GD, Gionis V, Hoenger A, Hamodrakas SJ. FT-Raman spectroscopy as diagnostic tool of Congo red binding to amyloids. Biopolymers 2003; 72: 185-192.
57. Roterman I, No KT, Piekarska B, Kaszuba J, Pawlicki R, Rybarska J, et al. Bis azo dyes - Studies on the mechanism of complex formation with IgG modulated by heating or antigen binding. J Physiol Pharmacol 1993; 44: 213-232.
58. Roterman I, Rybarska J, Konieczny L, Skowronek M, Stopa B, Piekarska B, et al. Congo red bound to α-1 proteinase inhibitor as a model of supramolecular ligand and protein complex. Comput Chem 1998; 22: 61-70.
59. Roterman I, Król M, Nowak M, Konieczny L, Rybarska J, Stopa B, et al. Why Congo red binding is specific for amyloid proteins - model studies and a computer analysis approach. Med Sci Monit 2001; 7: 771-784.
60. Skowronek M, Roterman I, Konieczny L, Stopa B, Rybarska J, Piekarska B. Why do Congo Red, Evans Blue and Trypan Blue differ in their complexation properties? J Comput Chem 2000; 21: 656-667.
61. Piekarska B, Konieczny L, Rybarska J, Stopa B, Zemanek G, Szneler E, et al. Heat-induced formation of a specific binding site for self-assembled Congo red in the V domain of immunoglobulin L chain λ. Biopolymers 2001; 59: 446-456.
62. Krol M, Roterman I, Piekarska B, Konieczny L, Rybarska J, Stopa B. Local and long-range structural effects caused by the removal of N-terminal polypeptide fragment from immunoglobulin L chain λ. Biopolymers 2003; 69: 189-200.
63. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem 2003; 278: 10842-10850.
64. Rybarska J, Konieczny L, Piekarska B, Stopa B, Roterman I. The detection of specific acute phase serum protein complexes and immune complexes by Congo Red binding to serum protein components. J Physiol Pharmacol 1995; 46: 221-231.
65. Huber R. Structural basis for antigen-antibody recognition. Science 1986; 233: 702-703.
66. Huber R. Bennett WS. Antibody-antigen flexibility. Nature 1987; 326: 334-335.
67. Calmettes P, Cser L, Rajnavolgyi É. Temperature and pH dependence of immunoglobulin G conformation. Arch Biochem Biophys 1991; 291: 277-283.
68. Smith TJ, Olson NH, Cheng RH, Chase ES, Baker TS. Structure of a human rhinovirus-bivalently bound antibody complex: Implications for viral neutralization and antibody flexibility. Proc Natl Acad Sci USA 1993; 90: 7015-7018.
69. Thouvenin E, Laurent S, Madelaine M-F, Rasschaert D, Vautherot J-F, Hewat EA. Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. J Mol Biol 1997; 270: 238-246.
70. Horgan C, Brown K, Pincus SH. Effect of H chain V region on complement activation by immobilized immune complexes. J Immunol 1992; 149: 127-135.
71. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 2000; 37: 1035-1046.
72. Horgan C, Brown K, Pincus SH. Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J Immunol 1993; 150: 5400-5407.
73. Horgan C, Brown K, Pincus SH. Alteration in H chain V region affects complement activation by chimeric antibodies. J Immunol 1990; 145: 2527-2532.
74. Jalon JC, Huser H, Blatt Y, Pecht I. Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide. Biochemistry 1975; 14: 5308-5311.
75. Harada S, Takagi S, Kosada Y, Kondo E. Hinge region of human IgG2 protein: Conformational studies with monoclonal antibodies. Mol Immunol 1992; 29: 145-149.
76. Zemanek G, Rybarska J, Stopa B, Piekarska B, Spolnik P, Konieczny L, et al. Protein distortion-derived mechanism of signal discrimination in monocytes revealed using Congo red to stain activated cells Folia Histochem Cytobiol 2003; 41: 113-124.
77. Jones S, Smith DP, Radford SE. Role of the N-terminal and C-terminal strands of Beta 2-Microglobulin in amyloid formation at neutral pH. J Mol Biol 2003; 330: 935-941.
78. Esposito G, Michelutti R, Verdone G, Viglino P, Hernández H, Robinson CV, et al. Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci 2000; 9: 831-845.
79. Ma B, Nussinov R. Molecular dynamics simulation of the unfolding of β2-microglobulin and its variants. Protein Eng 2003; 16: 561-575.
80. Bryksa BC Tanaka T, Yada RY. N-terminal modifications increase the neutral pH stability of pepsin. Biochemistry, 2003; 42, 13331-13338.
81. Ishikawa N, Chiba T, Chen LT, Shimizu A, Ikeguchi M, Sugai S. Remarkable destabilization of recombinant a-lactalbumin by an extraneous N-terminal methionyl residue. Protein Eng 1998; 11: 333-335.
82. Guddat LW, Shan L, Fan ZC, Andersen KN, Rosauer R, Linthicum DS, et al. Intramolecular signaling upon complexation. FASEB J 1995; 9: 101-106.
83. Oda M, Kozono H, Morii H, Azuma T. Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int Immunol 2003; 15: 417-426.